** Eli Lilly LLY.N shares dip 1.4% premarket to $872.32 after HSBC double downgrades rating to "reduce" from "buy"
** Brokerage also cuts TP to $700 from $1150, saying there is "too much optimism in the price"
** HSBC says obesity drug sector is sensitive to macro environment and sector's growth risk due to higher unemployment numbers is unknown
** "We prefer Novo (Nordisk) over Lilly at the current share price", HSBC adds
** Brokerage also downgrades Roche ROG.S, Biogen BIIB.O to "hold" from "buy," citing forex and China diagnostics risks for Roche and slow Alzheimer's adoption for Biogen
** 23 out of 29 analysts rate stock "buy" or higher, 5 "hold" and 1 "sell", median PT is $1000, as per LSEG data
** YTD, Of last close, LLY up 14.6%, ROG up 3.6% and BIO down 22.3%
(Reporting by Twesha Dikshit)
((Twesha.Dikshit@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.